糖尿病药物治疗英文

演讲人：日期：糖尿病药物治疗英文IntroductiontoDiabetesMellitusOverviewofDiagnosticMedicationsOralHydraulicAgents(OHAs)InsulinTherapyforDiabetesMellitus目录01IntroductiontoDiabetesMellitusDefinitionDiabetesMellitus(DM)isametabolicdisordercharacterizedbyhyperglycemiaresultingfromdefectsininsulinsecretion,insulinaction,orbothTypesofDiabetesThereareseveraltypesofdiabetes,includingType1DM(insulindependentdiabetesmellitus),Type2DM(noninsulindependentdiabetesmellitus),geostaticdiabetes,andotherspecifictypescausedbygeneticdefectsorendocrinesDefinitionandTypesofDiabetesEpiologyTheincidenceandpresenceofdiamondsvarywidelyacrossdifferentregionsandpopulationsItisamajorhealthproblemworldwide,affectingmillionsofpeopleRiskFactorsRiskfactorsfordevelopingdiabetesincludeobjectivity,seasonallifestyle,unhealthydiet,familyhistoryofdiabetes,culturalbackgrounds,andincreasingageEpidemiologyandRiskFactorsInsulinDeficiencyType1DMischaracterizedbytheconstructionofbetacellsinthepancreas,leadingtoabsoluteinsulindeficiencyInsulinResistanceType2DMisassociatedwithinsulinresistance,wherethebody'scellshavelessresponsetotheeffectsofinsulinThiscanbecombinedwithrelativeinsulindeficiencyHyperglycemiaUncontrolleddiabetesleadstohyperglycemia,whichcancauselongtermcomplicationssuchasmicrovasculardamage(affectingtheeyes,kidneys,andnerves)andmicrovasculardisease(affectingtheheartandbloodvessels)PathophysiologyofDiabetesClinicalManifestationsandDiagnosisSymptomsofdiamondsincludingpolyuria(frequenturination),polypsia(increasedthird),polyphagia(increasedappearance),weightlossdesignincreasedappearance,facade,andblurredvisionClinicalManifestationsDiagnosisofdiamondsisbasedonbloodglucosemeasurementsFastingplasmaglucose(FPG),oralglucosetolerancetest(OGTT),andrandomplasmaglucose(RPG)arecommonlyusedtestsAdditionally,glycatedhemoglobin(HbA1c)isausefulindicatoroflongtermglycomiccontrolDiagnosis02OverviewofDiagnosticMedicationsThesedrinkslowerbloodglucoselevelsbystimulatinginsulinrelease,increasinginsulinsensitivity,ordelayingtheabsorptionofcarbohydratesOralhypoglycemicagentsTheseareusedtoreplaceorsupplementinsulinproductioninpeoplewithdiabetes,specificallytype1diabetesInsulinandinsulinanalysisThesedrugsstimulateinsulinproduction,decreaseglucosesecretion,andslowgastricemptying,leadingtolowerbloodglucoselevelsGLP-1receptoragonistsThesedrugsworkbyblockingthereabsorptionofglucoseinthekidneys,leadingtoitsexcessintheurineandlowerbloodglucoselevelsSGLT2inhibitorsClassificationofDiabeticDrugsSimulationofinsulinrelease:Somebugs,suchassulfonylureas,workbystimulatingthepancreastoproducemoreinsulinDelayingcarbohydrateabsorption:Alphaglucoseinhibitorsslowdownthebreakdownofcarbohydratesintheessence,reducingtherateatwhichglucoseentersthebloodstream单击此处添加正文，文字是您思想的为了最终呈现发布的。单击此处添加正文文字是您思。文字是您思。单击此处添加正文文字是您思。文字是您思。4行*21字单击此处添加正文，文字是您思想的为了最终呈现发布的。单击此处添加正文文字是您思。文字是您思。单击此处添加正文文字是您思。文字是您思。4行*21字MechanismsofActionTherapeuticindicationsandcontainmentType1diabetesInsulintherapyisessentialforthemanagementoftype1diabetes,astheseindividualscannotproduceinsulinontheirownType2diabetesOralhydroglycemicagents,insulin,oracombinationofbothmaybeusedtotreattype2diabetes,dependingontheseverityoftheconditionandthepatient'sresponsetotreatmentGestationaldiamondsInsulinororalhydrographicalagentsmaybeusedtotreatGestationaldiamonds,dependingontheseverityoftheconditionandpreferencesofthetreatingphysicianContainmentofdiamondscompositesPropmanagementofdiamondscanhelptopreventordelaythedevelopmentofcompositessuchasretinopathy,neuropathy,andneuropathyTherapeuticindicationsandcontainmentHypogenemiaOverdoingonhydroglycemicagentsortakingthemincombinationwithotherbugsthatlowerbloodglucoselevelscanleadtohydroglycemia,apotentiallydangerousconditioncharacterizedbylowbloodsugarlevelsReverseEffectsandDrugInteractionsWeightgainSomehydroglycemicagents,suchassulfonylureasandthiazolidinediones,maycauseweightgainasasideeffectGastrointestinaleffectsDrugslikemetforminandalphaglucosidaseinhibitorsmaycausegastrointestinalsideeffectssuchasnasea,vomiting,anddiarrheaReverseEffectsandDrugInteractionsDruginteractionsManyhypoglycemicagentscaninteractwithotherdrugs,alteringtheireffectsorincreasingtheriskofsideeffectsItisimportantforpatientstoinformtheirdoctorsaboutallthemedicinestheyaretakingtoavoidpotentialinteractionsReverseEffectsandDrugInteractions03OralHydraulicAgents(OHAs)123SimulatethereleaseofinsulinfromthepancreasMechanismofActionGlipizide,Glyburide,GlimepirideCommonlyuseddrinksHypogenemia,weightgainSideEffectsSulfonylureas(SUs)03SideEffectsGastrointestinaldiscomfort,lacticacidosis(rare)01MechanismofActionReduceglucoseproductionbytheliverandincreaseinsulinsensitivity02CommonlyuseddrinksMetforminBiguanides(Metformin)IncreaseinsulinsensitivitybyactingonfatcellsMechanismofActionPioglitazone,RosiglitazoneCommonlyuseddrinksWeightgain,fluidretention,increasedriskofframesSideEffectsThiazolidinediones(TZDs)SlowdownthedigestionofcarbohydratesinthesmallintentionMechanismofActionAcarbose,MiglitolCommonlyuseddrinksGastrointestinaldiscomfort,flatnessSideEffectsAlphaGlucosidaseInhibitors(AGIs)DPP-4InhibitorsMechanismofAction:Preventthebreakdownofincrementalhornets,whichstimulatesinsulinreleaseCommonlyusedDPP-4Inhibitorsplugs:Sitagliptin,Saxagliptin,LinagliptinDPP-4InhibitorsSideEffects:Nasopharyngitis,headacheSGLT2InhibitorsMechanismofAction:Preventthereactionofglucoseinthekidneys,leadingtoitsexceptionintheurineCommonlyusedSGLT2Inhibitorsbugs:Canagliflozin,Papagliflozin,EmpagliflozinSGLT2InhibitorsSideEffects:Increasedriskofurinarytractinfections,generalinfectionsDPP-4InhibitorsandSGLT2Inhibitors04InsulinTherapyforDiabetesMellitusRapidactinginsulinTheseinsulinbegintoworkwithin15minutesafterinjectionandlastfor2-4hoursTheyaretypicallyusedbeforemealstocontrolposttraumaticbloodglucoselevelsShortactinginspirationsTheseinspirationsreachtheirpeakactivitywithin2-4hoursafterinjectionandlastfor5-8hoursTheyarecommonlyusedincombinationwithlongactinginsulintoprovidebasiccoverageTypesofInsulinPreparationsTypesofInsulinPreparationsIntermediateactinginsulinTheseinsulinreachtheirpeakactivitywithin4-12hoursafterinjectionandlastfor12-18hoursTheyareoftenusedasabasicinsulinincombinationwithrapidorshortactinginsulinformediancoverageLongactinginsulinTheseinsulinprovideasteady,slowreleaseofinsulinovera24hourperiod,providingbasiccoveragewithoutsignificantpeaksInsulinistypicallyadministeredviasubcutaneousinjectionusingasystolic,insulinpen,orinsulinpumpTheinjectionsiteshouldberotatedtoavoidlipodystrophyandensureconsistentabsorptionSomerapidactinginsulinareavailableinanInhaledformforpatientswhoprefernottoinjectHowever,thisrouteofadministrationisnotwidelyusedduetoconcernsaboutlungfunctionandtheneedforspecialequipmentInsulinpumpsaresmalldevicesthatdelivercontinuousbasicratesofinsulinaswellasbolusdosformealsandcorrectionsTheyareprogrammedbasedonthepatient'sindividualneedsandrequirefrequentmonitoringandadjustmentSubcutaneousinjectionInhaledinsulinInsulinpumpsAdministrationRoutesandDosageFormsBasalbolusregionThisregioninvolvestheadministrationoflongactinginsulintoprovideBasalcoverageandfast-orshortactinginsulinbeforemealstocontrolposttransitionalbloodglucoselevelsThedosareadjustedbasedonbloodglucosemonitoringresultsandthepatient'sindividualneedsPremiuminsulinregulationsPremiuminsulincontainsacombinationofintermediateandfast-orshortactinginsulininafixedratioTheyarestylishlyadministeredtwodaysbeforebreakfastanddinnerandprovidebothbasicandpracticalcoverageThedoscanbeadjustedbasedonbloodglucosemonitoringresultsInsulinRegimensandAdjustmentsInsulinpumptherapyInsulinpumptherapyinvolvesthecontinuousfusionofrapidactinginsulinthroughacatalystplacedundertheskinThepumpisprogrammedtodeliverbasalratesofinsulinaswellasbolusdosformealsandcorrectionsFrequentbloodglucosemonitoringisrequiredtoadjustthepumpsettingsanddosesInsulinRegimensandAdjustmentsRegularbloodglucosemonitoringFrequentbloodglucosemonitoringisessentialtoidentifyhypo